Similarly, the use of LPS-derivative MPL for TLR4 stimulation and TLR7 agonist imiquimod has been restricted to vaccine formulations against HPV-associated cervical cancers and to topical treatments for basal-cell skin carcinomas, respectively[10]. This evidence concerns the gene TLR7 and cervical carcinoma.